Abstract:Background Candida species are commonly detected as colonizers of the oral cavity; candidiasis or candidemia can develop in patients who are immunocompromised. Use of topical or inhaled glucocorticoids can alter the spectrum of Candida species and can promote oral candidiasis. The present study aims to evaluate the diversity of Candida species in the oral cavity and their susceptibility to antifungal agents in patients undergoing treatment with systemic glucocorticoids (SGCs) compared with non-users. Methods We conducted a descriptive, analytical, cross-sectional study that enrolled 120 patients with oral problems who were undergoing treatment with SGCs and who were admitted to the hospital of the First Affiliated Hospital, College of Medicine, Zhejiang University and Zhejiang Hospital, Hangzhou, China, between February 2019 and September 2019. One hundred and twenty age-and sex-matched patients were recruited as the SGC non-user control group. Demographic data included oral complaints and underlying diseases; symptoms of oral candidiasis were identified on physical examination. Candida species were collected using a concentrated oral rinse. Identification of fungal isolates was based on conventional phenotypic methods assisted by DNA sequence analysis of the internal transcribed spacer (ITS) rDNA gene region. Antifungal activities of anidulafungin, amphotericin B, micafungin, caspofungin, 5-flucytosine, posaconazole, voriconazole, itraconazole, and fluconazole were evaluated using the Sensititre YeastOneTM YO10 panel supplemented by the CLSI-M27-A3 protocol. Results Fifty-two (43.33%) out of the 120 patients undergoing with SGCs were diagnosed with oral candidiasis, compared with 14 (11.67%) of the non-users (P < 0.05). Likewise, we collected 88 strains from 73.33% of the SGC users compared with only 48 (40%) from non-users (P < 0.05). Candida albicans was detected most frequently in both groups (45.45% vs 66.67%, respectively; P = 0.033); the overall frequency of non-Candida albicans (NCA) strains isolated from patients treated with SGCs were significantly higher than that identified among non-users (51.14% vs 33.33%, respectively; P = 0.046), although there were no significant differences concerning any single species of NCA. Resistance of C. albicans to itraconazole (P = 0.004) and fluconazole (P = 0.001) was significantly higher in patients treated with SGCs than in non-users; however, echinocandins, amphotericin B, voriconazole, and posaconazole were all active against strains from both participant groups with no significant differences detected. Conclusion Taken together, our findings indicate that SGC therapy may result in an increased prevalence of oral candidiasis as reflected by the clinical presentations and strains isolated; these findings were also associated with an increased frequency of NCA strains. SGC therapy was also associated with an increased frequency of C. albicans strains that were resistant to both itraconazole and fluconazole. The impact of SGC therapy on Candida species in the oral cavity requires further study.

Glucocorticoid-induced gastrointestinal complications and prophylaxis

A Narrative Review of the Role of Glucocorticoid Receptors in Prostate Cancer: Developments in Last 5 Years

Oral Prevalence of Candida Species in Patients Undergoing Systemic Glucocorticoid Therapy and the Antifungal Sensitivity of the Isolates

Interpretation of Application of Glucocorticoids in Minimally Invasive Interventional Treatment for Pain (chinese Expert Consensus):The Severe Side Effects Induced by Glucocorticoids in Epidural Injection and Its Prevention

Application of glucocorticoid in common digestive diseases

Use of glucocorticoids in the management of immunotherapy-related adverse effects

Current status and influencing factors of prophylactic use of proton pump inhibitors in internal medicine inpatients receiving glucocorticoid therapy

Effect and its clinical significance of different dose of glucocorticoids on inflammation mediators in patients with acute exacerbation of chronic obstructive pulmonary diseases

Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review

Gut microbiota dysbiosis and decreased levels of acetic and propionic acid participate in glucocorticoid-induced glycolipid metabolism disorder

Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment

Molecular Mechanisms of Glucocorticoid-Induced Insulin Resistance

Glucocorticoid-Induced Hyperglycemia: A Neglected Problem

Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis

Glucocorticoid Treatment Strategies in Liver Failure

An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance

Minimizing complications from systemic glucocorticosteroid use

Treatment of Inflammatory Bowel Diseases with Glucocorticoid Purine Analogue

Current Status of Glucocorticoid Usage in Solid Organ Transplantation

Chronic glucocorticoid management in neuromuscular disease: A survey of neuromuscular neurologists

Long-term side effects of glucocorticoids